3 articles with Genentech, Inc.
Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients 2 years of age and older.
Genentech’s Tecentriq (Atezolizumab) Improves Overall Survival as a First-line Monotherapy in Certain People With Advanced Non-small Cell Lung Cancer
Genentech, a member of the Roche Group, announced positive data from the Phase III IMpower110 study evaluating Tecentriq® as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations.
FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels
The U.S. Food and Drug Administration approved Rituxan injection to treat granulomatosis with polyangiitis and microscopic polyangiitis in children 2 years of age and older in combination with glucocorticoids.